All News

lupus SLE

Obinutuzumab Efficacy in Active Lupus Nephritis

Jack Cush, MD

A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.

Read Article
RheumNow Podcast square

Drug Naming Games (2.7.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.

Read Article
cannabis,weed,marijuana

Cannabis Hospitalizations and Mortality Risk

Jack Cush, MD

A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death. 

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

Is Rheumatoid Arthritis Becoming Milder?

Jack Cush, MD

A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.

Read Article
pill,pain,med,hand

Pain Management in Rheumatoid Arthritis

Jack Cush, MD

BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.

Read Article
Sjogren,board

BSR Guideline on Management of Sjögren disease

Jack Cush, MD

The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease. 

Read Article
Knee.pain_.ice_.injury_0.jpg

Blood Flow Restriction to Reduce Pain in Knee OA

MedPage Today

A technique now widely used in sports medicine to speed recovery from leg injuries helped reduce symptoms and improve function in people with osteoarthritis (OA) of the knee, a randomized trial showed.

Read Article
ICYMI: Treatment of sclerosing skin disease: -Progression: inflammation➡️sclerosis➡️ atrophy -Existing therapies target inflammation not sclerosis-poorly developed ttx for sclerosis -First aspect is determining disease state, depth of involvement, extracutaneous manifestations… https://t.co/lYQRW2yDRG https://t.co/DQZjYKS2Ks

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2025 @RheumNow JAKi in DM: @JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response 145 case reports for tofa, bari, ruxolitinib. Role in helping calcinosis? Pruritu? Brepocitinib (JAK1/TYK2i) study

Eric Dein ericdeinmd ( View Tweet)

#HOT #topic Will #Rx of #PsO PREVENT onset of #PsA Well, maybe 🤔 Alexis R Ogdie ⁦@RheumNow⁩ #RNL2025 70% of #psoriatic #arthritis is preceded by #psoriasis Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr

Links:

Janet Pope Janetbirdope ( View Tweet)
Michele Petri @RheumNow #RNL2025 1 mg of prednisone -> 3% increased risk of damage Taper quickly, withdrawal slowly Make sure background therapy is on - monitor therapy with HCQ levels, early use of additional Rx https://t.co/pjFNcg99ed

Links:

Eric Dein ericdeinmd ( View Tweet)
Can #AI help us determine the 👇 Right drug At Right time Pipe dream? Or to use #artificial #intelligence term ➡️ a #hallucination? garbage in ➡️➡️garbage out Most predictions of drug response are same: multimorbid multiRx failures Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl

Links:

Janet Pope Janetbirdope ( View Tweet)
Pain Management in Rheumatoid Arthritis BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.… https://t.co/1rcTxpQxxT https://t.co/s20bg5FJqQ
Dr. John Cush RheumNow ( View Tweet)
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush RheumNow ( View Tweet)
Participation is Up! (1.31.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. We also have two call-in cases on "Ask Cush Anything". https://t.co/kxMkDW5X8c https://t.co/AjIuNzk7co

Links:

Dr. John Cush RheumNow ( View Tweet)
Celecoxib Lowers Colon Cancer Recurrence Risk The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to… https://t.co/tIoMtRlwKt https://t.co/fzOAplwJLi
Dr. John Cush RheumNow ( View Tweet)
RHEUMS! Please check out this important Survey on Cannibis/THS/CBD use in Rheumatology. This is a short survey (Ive done it) from the Rheumatology Research Foundation, FORWARD and the National Databank folks. We need to know more here; especially from you1 Link:… https://t.co/0KYbgqvceq https://t.co/JeO8hV0luB
Dr. John Cush RheumNow ( View Tweet)
Adalimumab Withdrawal in Uveitis Patients Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or… https://t.co/J1CRgC3GJz https://t.co/8eOSvl5zZm
Dr. John Cush RheumNow ( View Tweet)
Getting to Remission - Without Biologics Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.… https://t.co/knadKyxIpb https://t.co/OVSauZeetx
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×